ACQUISITION OPPORTUNITIES We have acquired and successfully integrated five services acquisitions since IPO in mid2014 all of which have been earnings enhancing. Strategic acquisitions which add specialist skills andor geographic coverage to our services offering remain key to our growth strategy. PRODUCT DEVELOPMENT UPSIDE We have economic interests in five drug development programmes through codevelopment partnerships together with two lead products from our whollyowned Haemostatix subsidiary. A milestone event from any one of these interests could have a material positive impact on Ergomed. DEBT FREE NET CASH POSITION Ergomeds cash at hand at 31 December 2017 was 3.2 million with zero debt. We retain the flexibility to access the capital markets andor leverage our balance sheet for strategic acquisitions as appropriate. INVESTMENT CASE 1. Source Zion Research 2014 2. Source Global Market Insights 2016 3. Source Global Data 2016 4. Source Evaluate Pharma Orphan Drug Report 2017 12 Ergomed plc Annual Report and Accounts 2017 CHIEF EXECUTIVE OFFICERS REVIEW DELIVERING ON GROWTH I am pleased to report on another year of strong growth in our service businesses and one which has also seen clinical success. We see significant opportunities to build on the foundations we have established in high growth areas within the pharmaceutical services market and specifically to take leadership positions in pharmacovigilance and orphan drug development services. We believe this will deliver further growth and shareholder value in the future. Services Overall it was a strong year within the services businesses. New business won in 2017 of 54 million up 29 on 2016 helped drive net service revenue growth of 36 to 39.6 million. Total service revenue including reimbursement revenue increased 21 to 47.6 million. EBITDA adjusted for the year was 2.8 million compared with 2.8 million in 2016. RD expense related to the development of the Haemostatix products was 2.7 million in 2017 and 1.2 million in 2016. The EBITDA adjusted of our services businesses excluding RD was 5.5 million in 2017 compared with 4.0 million in 2016. Drug Safety Medical Information DSMI The DSMI business which comprises the PrimeVigilance and PharmInvent companies performed exceptionally strongly. Net service revenue from the DSMI segment increased 68 to 22.2 million in 2017 from 13.3 million in 2016. Excluding the PharmInvent acquisition completed in November 2016 organic growth of the DSMI segment was 35. PharmInvent was acquired in November 2016 and immediately successfully collaborated with PrimeVigilance to provide a comprehensive pharmacovigilance service offering to existing and new clients of both companies. The integration was completed early in 2018 with both companies now operating under the PrimeVigilance brand led by Dr Jan Petracek. PrimeVigilance now employs over 450 employees with hubs in Guildford UK Belgrade Serbia Prague Czech Republic Boston USA and Zagreb Croatia. PrimeVigilance which is already a significant investor in information technology has initiated the implementation of robotic process automation for certain routine pharmacovigilance processes resulting in significant improvements in efficiency and accuracy. PrimeVigilances strategy of investing in people and technology is designed to drive further growth with the aim of becoming the global leader in pharmacovigilance by 2020. The global pharmacovigilance market is forecast to grow to more than 8Bn by 2024 from around 3Bn in 2015 with contract outsourcing forecast to expand from around 30 of the market in 2015 to approximately 50 in 2024. Source Global Market Insights 2016. Contract Research Services CRS Net service revenue from the CRS segment increased 9 to 17.4 million in 2017 from 15.9 million in 2016. Excluding the PSR acquisition October 2017 organic growth was 3. Consistent with our acquisition strategy of adding specialist skills andor geographic coverage PSR was acquired in October 2017 for a total consideration of up to 5.7 million 5.1 million. PSR is a specialist contract research organisation based in The Netherlands that specialises in the development of orphan drugs for rare diseases. Orphan drug development is a growing area with up to 30 million people worldwide estimated to suffer from rare diseases Source Evaluate Pharma Orphan Drug Report 2017. The logistical regulatory and operational complexities associated with orphan drug trials require specialised approaches. PSR combined with Ergomeds site management organisation and study physician groups is ideally suited for efficient management of these types of trials. The Companys goal is to become the leading global contract research organisation for orphan drug development and overall to continue to outpace the market for clinical research services. Stephen Stamp Chief Executive Officer 13 Ergomed plc Annual Report and Accounts 2017 Financial statements Governance Strategic report New Business Won 54m 29 Contracted Order Backlog 88m 26 Net Service Revenue 39.6m 36 Services EBITDA adjusted 5.5m 1.5m Global demand for quality outsourced drug safety services and drug development remains strong and Ergomed continues to benefit from these trends. Ergomed ended 2017 with a total backlog of contracted work with a value to be invoiced in future years of approximately 88 million 2016 70 million. Product development Codevelopment A new codevelopment deal with Allergy Therapeutics plc LSE AGY was announced in December 2017.The multi study codevelopment partnership is aimed at supporting the commercialisation of Allergy Therapeutics OraiVac platform and could include studies of three OraiVac products. The Company also announced the following updates during the year Ferrer In February 2017 Ferrer announced data from the successful Phase II study of lorediplon in insomnia. Aeterna Zentaris NASDAQ AEZS TSX AEZ In May 2017 Aeterna Zentaris announced termination of their programme after Zoptrex showed no treatment benefit over doxorubicin control. CELSCI NYSE CVM The FDA lifted the clinical hold for Multikine in August 2017 and the Phase III study in head and neck cancer is continuing as initially planned. We believe our codevelopment pipeline continues to offer potential upside as programmes progress and move towards commercialisation.